Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group.
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group.
复制标题
表柔比星和紫杉醇的剂量密集序贯化疗与作为一线化疗的组合在晚期乳腺癌中的比较：由希腊肿瘤合作组进行的一项随机研究。
DOI：
10.1200/jco.2001.19.8.2232
复制
发表时间：
2001
期刊：
影响因子：
--
通讯作者：
M. Dimopoulos
中科院分区：
文献类型：
--
作者：
G. Fountzilas;C. Papadimitriou;U. Dafni;D. Bafaloukos;D. Skarlos;L. Moulopoulos;E. Razis;H. Kalofonos;G. Aravantinos;E. Briassoulis;P. Papakostas;K. Abela;E. Gogas;P. Kosmidis;N. Pavlidis;M. Dimopoulos
目的
比较表阿霉素和紫杉醇两种不同方案作为一线化疗方案治疗晚期乳腺癌（ABC）的疗效。
患者和方法
从1997年10月至1999年5月，183名符合条件的ABC患者进入研究。A组（93例患者）的化疗包括4个周期的表阿霉素，剂量为110 mg/m2，随后是4个周期的紫杉醇，剂量为225 mg/m2，输注3小时。所有周期每2周重复一次，并给予粒细胞集落刺激因子支持。B组（90例患者）的治疗方案包括表阿霉素（80 mg/m2），紧接着紫杉醇（175 mg/m2，3小时输注），每3周1次，共6个周期。
结果
A组共有79例患者（85%）完成治疗，B组共有72例患者（80%）完成治疗。两组中表阿霉素的中位相对剂量强度为0.96，A组和B组中紫杉醇的中位相对剂量强度分别为0.96和0.97。A组完全缓解率较高（21.5% vs9%，P =.02）。然而，两组的总体缓解率无显著差异（55% vs42%，P = 0.10）。伴随治疗时更常观察到重度中性粒细胞减少症。中位随访16.5个月后，A组中位进展时间为10个月，B组为8.5个月（P = 0.27），中位生存期分别为21.5个月和20个月（P = 0.17）。
结论
目前的研究未能证明剂量密集的依皮鲁肽和紫杉醇序贯给药与同一天给予的两种药物联合给药之间的总体缓解率存在显著差异，尽管序贯治疗导致完全缓解率显著更高。
PURPOSE
To compare the efficacy of two different schedules of epirubicin and paclitaxel, as first-line chemotherapy, in patients with advanced breast cancer (ABC).
PATIENTS AND METHODS
From October 1997 until May 1999, 183 eligible patients with ABC entered the study. Chemotherapy in group A (93 patients) consisted of four cycles of epirubicin at a dose of 110 mg/m(2) followed by four cycles of paclitaxel at a dose of 225 mg/m(2) in a 3-hour infusion. All cycles were repeated every 2 weeks with granulocyte colony-stimulating factor support. The therapeutic regimen in group B (90 patients) consisted of epirubicin (80 mg/m(2)) immediately followed by paclitaxel (175 mg/m(2) in a 3-hour infusion) every 3 weeks for six cycles.
RESULTS
In total, 79 patients (85%) in group A and 72 patients (80%) in group B completed treatment. The median relative dose-intensity of epirubicin was 0.96 in both groups, and that of paclitaxel was 0.96 and 0.97 in groups A and B, respectively. The complete response rate was higher in group A (21.5% v 9% P =.02). Nevertheless, there was no significant difference in the overall response rate between the two groups (55% v 42%, P =.10). Severe neutropenia was more frequently observed with concurrent treatment. After a median follow-up of 16.5 months, median time to progression was 10 months in group A and 8.5 months in group B (P =.27), and median survival was 21.5 and 20 months, respectively (P =.17).
CONCLUSION
The present study failed to demonstrate a significant difference in overall response rate between dose-dense sequential administration of epirubicin and paclitaxel compared with the combination of the two drugs given on the same day, even though the sequential treatment resulted in a significantly higher complete response rate.
DOI：
--
发表时间：
1972
期刊：
--
影响因子：
--
作者：
D. Cox
通讯作者：
D. Cox
阿霉素和紫杉醇加粒细胞集落刺激因子治疗转移性乳腺癌的 II 期试验：东部肿瘤合作组研究。
DOI：
10.1200/jco.1999.17.12.3828
发表时间：
1999
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Sparano,JA;Hu,P;Rao,RM;Falkson,CI;Wolff,AC;Wood,WC
通讯作者：
Wood,WC